BC Extra | Jan 17, 2020
Financial News

Sofinnova Partners vet Tordjman launches Jeito with €200M first biotech fund

Paris-based Jeito Capital launched Monday with the €200 million ($223.1 million) close of its first fund, which the firm will invest in 15 therapeutics start-ups, primarily in Europe. Jeito founder and CEO Rafaèle Tordjman was...
BC Extra | Aug 15, 2019
Company News

Management tracks: New executives at Pfizer spinouts Cerevel and SpringWorks

Cerevel Therapeutics LLC (Boston, Mass.) hired Orly Mishan as CBO, a newly created role. She was principal and a founding member of Bain Capital Life Sciences, which launched the Pfizer Inc. (NYSE:PFE) spinout with $350...
BioCentury | Jan 5, 2019
Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
BioCentury | Jun 16, 2018
Finance

No easy way up

A prolonged period of underperformance at Allergan plc (NYSE:AGN) has activists agitating for change, but there likely aren’t any quick fixes. Looming competition and IP setbacks for key franchises, a mixed business development record and...
BioCentury | May 5, 2018
Finance

Splitting Ironwood

Ironwood Pharmaceuticals Inc. has accomplished what many biotechs aspire to but few achieve. It has built a high-growth GI business on the cusp of profitability, and discovered and developed a well-stocked pipeline of clinical candidates...
BC Week In Review | Oct 17, 2016
Clinical News

Kazano regulatory update

Japan approved an NDA from Takeda for Inisync alogliptin/metformin to treat Type II diabetes. The fixed-dose combination of alogliptin and metformin is approved as Kazano in the U.S. and as Vipdomet in the EU for...
BioCentury | Aug 15, 2016
Finance

Finesse with Linzess

Thanks to a relatively flat expense line in 2Q16, Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) almost doubled proceeds from its Linzess linaclotide deal with Allergan plc (NYSE:AGN). Going forward, the biotech expects to be able to deploy...
BC Extra | Mar 3, 2016
Company News

Management tracks

Infectious disease company Spero Therapeutics LLC (Cambridge, Mass.) named Cristina Larkin chief commercial officer. She was assistant VP at Forest Laboratories Inc. , which Allergan plc (NYSE:AGN) acquired. Protein degradation company Arvinas LLC (New Haven, Conn.)...
BC Extra | Sep 18, 2015
Company News

Management tracks

Neurology play Marathon Pharmaceuticals LLC (Northbrook, Ill.) named Jordon Dubow CMO and VP of clinical and medical affairs. Dubow was VP of medical affairs at Cynapsus Therapeutics Inc. (Toronto, Ontario). Regenerative medicine company Osiris Therapeutics...
BioCentury | Sep 14, 2015
Finance

Gaining leverage

Carl Icahn wants to buy up convertible notes of Vivus Inc. (NASDAQ:VVUS), and if the debt holders agree to his terms the financier would gain a major bargaining chip with the obesity play. Vivus shareholders...
Items per page:
1 - 10 of 1000
BC Extra | Jan 17, 2020
Financial News

Sofinnova Partners vet Tordjman launches Jeito with €200M first biotech fund

Paris-based Jeito Capital launched Monday with the €200 million ($223.1 million) close of its first fund, which the firm will invest in 15 therapeutics start-ups, primarily in Europe. Jeito founder and CEO Rafaèle Tordjman was...
BC Extra | Aug 15, 2019
Company News

Management tracks: New executives at Pfizer spinouts Cerevel and SpringWorks

Cerevel Therapeutics LLC (Boston, Mass.) hired Orly Mishan as CBO, a newly created role. She was principal and a founding member of Bain Capital Life Sciences, which launched the Pfizer Inc. (NYSE:PFE) spinout with $350...
BioCentury | Jan 5, 2019
Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
BioCentury | Jun 16, 2018
Finance

No easy way up

A prolonged period of underperformance at Allergan plc (NYSE:AGN) has activists agitating for change, but there likely aren’t any quick fixes. Looming competition and IP setbacks for key franchises, a mixed business development record and...
BioCentury | May 5, 2018
Finance

Splitting Ironwood

Ironwood Pharmaceuticals Inc. has accomplished what many biotechs aspire to but few achieve. It has built a high-growth GI business on the cusp of profitability, and discovered and developed a well-stocked pipeline of clinical candidates...
BC Week In Review | Oct 17, 2016
Clinical News

Kazano regulatory update

Japan approved an NDA from Takeda for Inisync alogliptin/metformin to treat Type II diabetes. The fixed-dose combination of alogliptin and metformin is approved as Kazano in the U.S. and as Vipdomet in the EU for...
BioCentury | Aug 15, 2016
Finance

Finesse with Linzess

Thanks to a relatively flat expense line in 2Q16, Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) almost doubled proceeds from its Linzess linaclotide deal with Allergan plc (NYSE:AGN). Going forward, the biotech expects to be able to deploy...
BC Extra | Mar 3, 2016
Company News

Management tracks

Infectious disease company Spero Therapeutics LLC (Cambridge, Mass.) named Cristina Larkin chief commercial officer. She was assistant VP at Forest Laboratories Inc. , which Allergan plc (NYSE:AGN) acquired. Protein degradation company Arvinas LLC (New Haven, Conn.)...
BC Extra | Sep 18, 2015
Company News

Management tracks

Neurology play Marathon Pharmaceuticals LLC (Northbrook, Ill.) named Jordon Dubow CMO and VP of clinical and medical affairs. Dubow was VP of medical affairs at Cynapsus Therapeutics Inc. (Toronto, Ontario). Regenerative medicine company Osiris Therapeutics...
BioCentury | Sep 14, 2015
Finance

Gaining leverage

Carl Icahn wants to buy up convertible notes of Vivus Inc. (NASDAQ:VVUS), and if the debt holders agree to his terms the financier would gain a major bargaining chip with the obesity play. Vivus shareholders...
Items per page:
1 - 10 of 1000